newsfilter
← Latest News
GlobeNewswire·

Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

RESET-Myositis® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data